FDA Issues Complete Response Letter for AstraZeneca COPD Drug Application

News
Article

AstraZeneca has received a complete response letter from FDA regarding its new drug application for a budesonide/glycopyrronium/formoterol fumarate triple-combination therapy for treating chronic obstructive pulmonary disease.

On Oct. 1, 2019, AstraZeneca announced that FDA has issued a complete response letter regarding a new drug application (NDA) the company submitted for PT010 (budesonide/glycopyrronium/formoterol fumarate), an inhaled triple-combination therapy and potential new medicine for patients with chronic obstructive pulmonary disease (COPD).

The NDA included data from a Phase III trial. The company will now work closely with FDA regarding the next steps, including submitting recent results from a second positive Phase III trial for review, which was not completed at the time the NDA was submitted.

PT010 was approved in Japan in June 2019 as Breztri Aerosphere for treating COPD and is under regulatory review in China, where it has been granted priority review by the National Medical Products Administration. It is also under regulatory review in the European Union.

Meanwhile, under the terms of an agreement to acquire Pearl Therapeutics Inc., AstraZeneca anticipates making a $150-million milestone payment upon US regulatory approval of PT010 for COPD. The payment would be the final development and regulatory milestone under that agreement.

Source: AstraZeneca

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes